Duvyzat®▼ (givinostat): interim advice on risk mitigation measures following reports of deaths in patients while taking givinostat
Safety Classified by Officially
There have been several reports internationally of deaths in patients with Duchenne muscular dystrophy (DMD) while being treated with Duvyzat® (givinostat). Following a review of these cases and associated evidence, the MHRA has proposed updates to the product information. Interim monitoring advice is being provided by the MHRA based on these proposals, pending independent review and finalisation of the MHRA’s position.
Advice for Healthcare Professionals to Provide to Patients:
This is an extract. The publication continues at the source.
Contains public sector information licensed under the Open Government Licence v3.0. Licence
Read the original at the source: https://www.gov.uk/drug-safety-update/duvyzat-r-v-givinostat-interim-advice-on-risk-mitigation-measures-following-reports-of-deaths-in-patients-while-taking-givinostat
Officially imported this from Medicines and Healthcare products Regulatory Agency’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.
Provenance
- Organization
- Medicines and Healthcare products Regulatory Agency — imported from official source
- Official source
- https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency.atom ATOM
- Imported
- November 05, 2026 13:02
- Versions
- 1 recorded
- Identity
-
https://www.gov.uk/drug-safety-update/duvyzat-r-v-givinostat-interim-advice-on-risk-mit...